Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Teva Pharmaceuticals has received US FDA approval for AJOVY (fremanezumab-vfrm) as a preventive treatment for episodic migraine in children and adolescents aged 6–17 who weigh at least 45 kilograms.

Eli Lilly and Company and the UK Government have announced a joint programme to develop innovative models of care for obesity ...

Eli Lilly and Company has announced positive topline results from its phase 3 BRUIN CLL-314 trial of Jaypirca (pirtobrutinib) ...

Sever Pharma Solutions has deepened its partnership with Silo Pharma to advance a novel ketamine-based implant designed to ...

Patients in Scotland with relapsed or refractory mantle cell lymphoma (MCL) after one line of treatment can now access ...

Celltrion has received US Food and Drug Administration approval for an expanded indication of AVTOZMA (tocilizumab-anoh) ...

New first-line option for patients with pMMR and dMMR tumours in England NICE has recommended KEYTRUDA (pembrolizumab) with ...

Nxera Pharma has launched a broad proprietary pipeline focused on next-generation therapies for obesity and related metabolic conditions. The pipeline is led by a new oral small molecule GLP-1 agonist ...